Switch of serotonergic descending inhibition into facilitation by a spinal chloride imbalance in neuropathic pain.
Franck AbyLouis-Etienne LorenzoZoé GrivetRabia Bouali-BenazzouzHugo MartinStéphane ValerioSara WhitestoneDominique IsabelWalid IdiOtmane BouchattaPhilippe De DeurwaerdereAntoine G GodinCyril HerryXavier FioramontiMarc LandryYves de KoninckPascal FossatPublished in: Science advances (2022)
Descending control from the brain to the spinal cord shapes our pain experience, ranging from powerful analgesia to extreme sensitivity. Increasing evidence from both preclinical and clinical studies points to an imbalance toward descending facilitation as a substrate of pathological pain, but the underlying mechanisms remain unknown. We used an optogenetic approach to manipulate serotonin (5-HT) neurons of the nucleus raphe magnus that project to the dorsal horn of the spinal cord. We found that 5-HT neurons exert an analgesic action in naïve mice that becomes proalgesic in an experimental model of neuropathic pain. We show that spinal KCC2 hypofunction turns this descending inhibitory control into paradoxical facilitation; KCC2 enhancers restored 5-HT-mediated descending inhibition and analgesia. Last, combining selective serotonin reuptake inhibitors (SSRIs) with a KCC2 enhancer yields effective analgesia against nerve injury-induced pain hypersensitivity. This uncovers a previously unidentified therapeutic path for SSRIs against neuropathic pain.
Keyphrases
- neuropathic pain
- spinal cord
- spinal cord injury
- pain management
- ultrasound guided
- chronic pain
- quality improvement
- multiple sclerosis
- adipose tissue
- cell therapy
- climate change
- stem cells
- binding protein
- metabolic syndrome
- high fat diet induced
- resting state
- type diabetes
- subarachnoid hemorrhage
- bone marrow
- insulin resistance
- amino acid
- blood brain barrier
- endothelial cells